Developments in Tau PET Imaging

Canadian Journal of Neurological Sciences

Volumn 41, Issue 5, 2014, Pages 547-553

  Zimmer, Eduardo Rigon ^a,b   Leuzy, Antoine ^a   Gauthier, Serge ^a   Rosa Neto, Pedro ^a  

^a MCGILL UNIVERSITY   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Dementia; positron emission tomography (PET); radiopharmaceuticals; tau; tauopathy

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN;

AMYLOID PLAQUE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; CEREBROSPINAL FLUID; DRUG UPTAKE; EX VIVO STUDY; EXAMINATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUMBAR PUNCTURE; MENTAL HEALTH; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CONFORMATION; RADIOCHEMISTRY; REVIEW; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; BRAIN; HUMAN; METABOLISM; PROCEDURES; SCINTISCANNING; TRENDS;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TAU PROTEINS; TAUOPATHIES;

EID: 84929319498     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2014.15     Document Type: Review

References (49)

1. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33(1):95-130.
2. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989;3(4):519-26.
3. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 1975;72(5):1858-62.
4. Cleveland DW, Hwo SY, Kirschner MW. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol. 1977;116(2):227-47.
5. Horio T, Hotani H. Visualization of the dynamic instability of individual microtubules by dark-field microscopy. Nature. 1986; 321(6070):605-7.
6. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70(4):532-40.
7. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32(3):150-9.
8. de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73(4):685-97.
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.
10. Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16.
11. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-13.
12. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59(4):627-9.
13. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002; 103(1):26-35.
14. Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med. 2010;48(5):603-7.
15. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134(Pt 4):1089-100.
16. Spies PE, Claassen JAHR, Slats D, Olde Rikkert MGM, Verbeek MMK, Kessels RPC. Cerebrospinal fluid tau and amyloid beta proteins do not correlate with cognitive functioning in cognitively impaired memory clinic patients. CNS Spectrum. 2010;15(9):588-93.
17. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739(2-3):240-50.
18. von Bergen M, Barghorn S, Li L, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276(51):48165-74.
19. Gotz J, Gladbach A, Pennanen L, et al. Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta. 2010;1802(10):860-71.
20. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316 (5825):750-4.
21. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9(12):677-86.
22. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54(8):1420-7.
23. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666-76.
24. Zhang W, Arteaga J, Cashion DK, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012;31(3):601-12.
25. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6): 1094-1108.
26. Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Transl Neurodegener. 2014;3(1):6.
27. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-25.
28. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001; 21(24):RC189.
29. Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem. 2009;109(2):623-30.
30. Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. Am J Pathol. 1993;143(2):565-78.
31. Harada R, Okamura N, Furumoto S, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging. 2013;40(1):125-32.
32. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-68.
33. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41(5):816-26.
34. Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry. 2004;43 (6):1694-703.
35. von Bergen M, Barghorn S, Muller SA, et al. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry. 2006;45(20): 6446-57.
36. Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014;6(1):11.
37. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38(1):171-84.
38. Langstrom B, Andren PE, Lindhe O, Svedberg M, Hall H. In vitro imaging techniques in neurodegenerative diseases. Mol Imaging Biol. 2007;9(4):161-75.
39. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5(6):363-75.
40. Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30(8):431-40.
41. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263-72.
42. Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Alterations in tau protein metabolism during normal aging. Dementia. 1996;7(2):95-103.
43. Wu L, Rosa-Neto P, Gauthier S. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol Diagn Ther. 2011;15(6):313-25.
44. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171-81.
45. Villemagne VL. The challenges of tau imaging. Future Neurol. 2012;7(4):409-21.
46. Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ. Human tau isoforms assemble into ribbonlike fibrils that display polymorphic structure and stability. J Biol Chem. 2010;285(35):27302-13.
47. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int. 2011;58(4):458-71.
48. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-7.
49. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003; 62(11):1087-95.